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ABSTRACT

A decrease in astrocyte function and viability has been linked to many neurodegenerative
diseases, including schizophrenia, major depressive disorders, Alzheimer’s disease, and
Amyotrophic Lateral Sclerosis (ALS). Previous research indicates that some estrogens may have
a positive effect on neuron and astrocyte viability. Estrogens’ effects on the brain are of interest
as estrogens are commonly prescribed as hormone replacement therapy to reduce the symptoms
of menopause in women. Unfortunately, these effects on are not completely understood. The
goal of the project was to discover if estrogen has any protective effect on astrocytes exposed to
oxidative stress. We measured the oxidative stress level of N1 1321 glial cells that were exposed
to 600pM hydrogen peroxide. The astrocytes were pretreated for one hour with one of four types
of estrogen at four concentrations ranging ffomlOnM -

IOJIM.

Two endogenous human

estrogens, 17 alpha-estradiol and 17 beta-estradiol, and two equine estrogens, equilin and
equilenin, were utilized. Only 17 alpha-estradiol showed a statistical difference in the oxidative
stress levels of astrocytes. However, the results indicate that differing estrogen concentration still
had no effect on the oxidative stress levels in unstressed astrocyte populations.
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INTRODUCTION

The importance of glial cells in the brain cannot be overstated. Glial cells function to
support neurons and comprise as much as 90% of the human brain (He and Sun, 2006). One of
the most common glial cells is the stellate-shaped astrocyte cell. Astrocytes have a variety of
essential functions in the central nervous system (CNS). As one function, astrocytes sustain
neurons by providing glycogen as a source of energy to fuel neurons (Reynolds, 2012).
In addition to providing crucial energy and nourishment, astrocytes are employed in a
multitude of other crucial brain functions related to sustainability. Notably, astrocytes are
involved in the maintenance of the extracellular ion concentration in the CNS, preserving the
permeable membrane known as the blood-brain barrier, and assisting in the repair and
regeneration of nervous tissue after an injury (Venkatesh et al., 2013). Astrocytes have also been
shown to be involved in neuronal migration by providing a natural scaffolding for neurons
(Venkatesh et al., 2013). Additionally, astrocytes have been associated with the reuptake of
neurotransmitters and the release of gliotransmitters in the brain (Agulhon et al., 2010).
Furthermore, astrocytes have been shown to assist with synaptogenesis by releasing proteins,
which help to increase the number of synapses formed between neurons (Barker and Ullian,
2008). Finally, there is even evidence that astrocytes of the subventricular zone may act as neural
stem cells. These astrocytes have been shown to be precursor cells to neuroblasts and ultimately
new neurons (Doetsch et al., 1999). Undoubtedly, astrocytes have numerous supportive functions
to nervous tissue.
Because astrocytes play such fundamental functions in the brain, it is not surprising that a
decrease in their function and viability has been linked to multiple neurological diseases. For
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instance, reduced astrocyte function has been connected to schizophrenia and other major
depressive disorders (Barres and Sloan, 2014). Also, a decline in astrocyte function has been
linked to many neurodegenerative diseases. In one example, Alzheimer’s disease, astrocyte
function is diminished by the accumulation of amyloid-P plaques, which eventually leads to
astrocyte cell death (Maragakis and Rothstein, 2006). In addition, Amyotrophic Lateral Sclerosis
(ALS) is associated with the loss of an astrocyte glutamate transporter, and Huntington’s disease
is linked to the alteration of astrocyte gap junctions. Astrocyte deficiency has also been
associated with both Alexander disease and Parkinson’s disease (Maragakis and Rothstein,
2006).
Noticeably, astrocytes play an important role in the neural functioning as evidenced by
the quantity of astrocytes in the CNS, the critical functions astrocytes contribute to neurons, and
the significant association of deteriorating astrocytes in neurodegenerative diseases. With this in
mind, it was of interest to study biological components that could increase or decrease the
viability of astrocytes. One such biological component of interest is the effect estrogen has on
astrocytes, and in particular, the effect that estrogen has on the oxidative stress levels in
astrocytes.
Estrogen’s effects on the brain are of interest for two major reasons. First, estrogen’s
effects on the brain are not yet completely understood, and second, estrogen is commonly
prescribed in hormone replacement therapy to reduce the symptoms of menopause in women.
According to the Mayo Clinic, menopause is a biological transformation period in women
characterized by decreased estrogen levels and is identified with an ending of both the menstrual
cycle and fertility. The progression into menopause is frequently associated with numerous
uncomfortable symptoms including hot flashes, sleeping problems, fatigue, mood changes, and
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increased urogenital sensitivity and dryness (Mehra 2014). To lessen these uncomfortable
symptoms, many women elect to take estrogen replacement therapy as a practical remedy. The
Mayo Clinic defines hormone replacement therapy as the addition of supplemental,
pharmaceutically produced hormones to replenish the natural hormones that the body no longer
naturally produces. However, the use of estrogen replacement therapy has been correlated with
both health benefits and detriments in different studies. Because estrogen’s effects on the brain
are not completely understood, the use of estrogen replacement therapy is controversial. The
controversy and contrasting results could conceivably stem from the type of estrogen used in
therapy, rather than all estrogen therapy.
Currently, menopausal symptoms are reduced through the use of Premarin, a drug
produced by Pfizer pharmaceutical company for estrogen replacement therapy. Premarin is
composed of equine estrogens, derived from pregnant mare urine. Specifically, Premarin is
comprised of two types of conjugated equine estrogens (CEEs), which include equilin and
equilenin. However, these equine estrogens are not naturally occurring in humans and the effects
of CEEs are largely unknown. There have been contending views in the literature regarding the
effects of CEEs. For instance, in healthy women, CEEs have been reported to increase the risk of
ischemic stroke (Hendrix et al. 2006). However, the combination of multiple CEEs has also been
shown to have neuroprotective effects (Zhao and Brinton, 2006). Ultimately, the use of CEEs is
currently controversial as it is unknown if the effects are beneficial or detrimental to women.
While CEEs are not naturally occurring in humans, there are three types of estrogens that
naturally occur in humans. These endogenous human estrogens include estrone (El), estriol (E3),
and the most common, estradiol (E2). One particular isomer of estradiol, 17 beta-estradiol (E2),
has been associated with neuroprotective and cardioprotective properties. Specifically, 17 beta-
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estradiol has been found to be neuroprotective in multiple ways. First, 17 beta-estradiol has been
shown to have apparent antioxidant properties that work to reduce oxidative stress in the brain
(Behl et al. 1997). Also, 17 beta-estradiol has also been revealed to protect the brain, and
specifically protect astrocytes, from ischemic injuries. This is thought to be due to 17 betaestradiol’s ability to reduce the harmful effects of oxygen and glucose deprivation (Guo et al.,
2012). One other estradiol isomer, 17 alpha-estradiol, has also displayed neuroprotective effects
similar to those of 17 beta-estradiol. In particular, 17 alpha-estradiol is effective in reducing
symptoms in both Alzheimer’s and Parkinson’s disease as well showing subsequent usefulness
following a stroke (Dykens et al., 2005). Moreover, the 17 alpha-estradiol isomer has even been
shown to increase neurogenesis and positively influence cell proliferation in a dose-dependent
manner (Barha et al., 2009). In essence, both 17 beta-estradiol and 17 alpha-estradiol have
demonstrated neuroprotective benefits.
The purpose of this study was to discover if different types of estrogens have either a
protective or detrimental effect on astrocyte cells that are exposed to oxidative stressful
conditions. Astrocytes were pretreated with estrogen for one hour, subsequently exposed to
oxidative stress, and then finally retreated with estrogen for two hours. These relatively shorter
estrogen treatments were chosen in order to determine if estrogen has an effect via a rapid
signaling pathway or a slower signaling pathway influencing transcription or translation. A
transcriptional or translational change would require a longer estrogen exposure time (possibly
between 24 - 48 hours) for estrogen to show an effect on astrocytes.
Also in this study, astrocytes were treated with either endogenous estrogens, which are
naturally occurring in humans or CEEs, which are not naturally occurring in humans, but are
often prescribed to post-menopausal women to combat the symptoms of menopause. This
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allowed us to discover if naturally occurring estrogens have similar or different effects when
compared with CEEs. The two endogenous human estrogens tested included: 17 alpha-estradiol,
17 beta-estradiol and the two conjugated equine estrogens tested included: equilin, and equilenin.
The four estrogens were also assessed at four different concentrations between lOnM -10p.M.
This allowed us to determine whether the estrogen concentration had an effect on oxidative stress
levels in astrocytes.

6

METHODS

Cells
In this study, we used GIBCO® Human Astrocytes (N1 1321), which are a human-based
astrocyte cell line sold by Life Technologies. The human astrocytes arrived cryopreserved in
liquid nitrogen. The initial portion of the experiment entailed preparing the culture of astrocyte
cells. The astrocytes were thawed in a water bath at 37°C. The cells were then placed in a T-75
flask culture vessel with 10 microliters Dulbecco’s Modified Eagle’s Medium (DMEM), a
complete astrocyte medium which also contained 10% Fetal Bovine Serum (FBS) and a 1%
antibiotic/antimycotic that was supplemented to the astrocyte media. The media was changed
approximately every two days. The culture vessel was incubated at 37°C in an atmosphere
containing 5% CO2. Incubation continued until cells became roughly 80-90% confluent, which
was determined using a microscope. Once confluent, the astrocytes were subcultured using 5
microliters trypsin-EDTA to free cells from the substrate. Next, using a Bio-Rad automated cell
counter, the concentration of cells in solution was adjusted to lxl 06 cells/mL. Finally, 200
microliters of the astrocyte solution was placed in 34 wells of a 96 well plate. Table 1
summarizes the treatment design for different astrocyte populations.
Astrocyte Treatment
The second portion of the experiment entailed pre-treating astrocytes, in vitro, with the
four hormones: 17 alpha-estradiol, 17 beta-estradiol, equilin, and equilenin. The astrocytes were
pretreated with 10 microliters of the estrogens for a final concentration of lOnM, lOOnM, 1 pM,
or 1 OpM. There was also a positive and negative control group of astrocytes, which were not pretreated with any estrogen. Next, half of the astrocytes were exposed to oxidative stress for one
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hour by adding 20 microliters hydrogen peroxide for a final concentration of 600 uM The other
half of the wells received 20 microliters PBS as a control. After one hour, all liquid was removed
and 200 microliters of fresh astrocyte media was added. The same astrocytes, which were
pretreated with the four estrogen concentrations earlier, were then again retreated with 10
microliters of their respective estrogen solutions and incubated for two more hours.
Oxidative Stress Assay
The last aspect of the experiment involved testing the astrocytes for oxidative stress using
flow cytometry on the Muse® system. To accomplish this, astrocytes were first removed from
each well by adding 100 microliters of trypsin-EDTA per well. Once removed, the astrocytes
were placed in centrifuge tubes containing 100 microliters of fresh media and centrifuged at
3000 rpm for three minutes. Next, all liquid was removed from the centrifuge tubes, and the
astrocytes were resuspended in 100 microliters of Muse® assay buffer. Then 10 microliters of
that resuspended cellular solution was added to 190 microliters of prepared Muse® working
solution, which allows the Muse® system flow cytometry assay to detect any reactive oxygen
species. Finally, the prepared working solution, now containing the astrocytes, was incubated for
thirty more minutes, and then each sample was tested via an oxidative stress assay on the Muse®
system using flow cytometry.
Statistical Analysis
The independent variables were +/- hydrogen peroxide treatment and the concentration of
estrogen. In total, there were five trials. Statistical significance of oxidative stress and estrogen
concentration was assessed, for each estrogen, using a two-way ANOVA and LSD post hoc test.
A p-value <0.05 indicated statistical significance.
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RESULTS

There was not a significant difference between the positive control of astrocytes stressed
with hydrogen peroxide and the negative control of unstressed astrocytes (1-way ANOVA,
Stressed, Fi,g=0.508, P=0.496; Figure 1). The 17 alpha-estradiol assay did show a statistically
significant difference when comparing estrogen treatment. However, there was no statistical
significant difference across the four concentrations of 17 alpha-estradiol used (2-way ANOVA,
Stressed, Fi,32=7.670, P=0.009; Concentration, F3,32=0.046, P=0.987; Figure 2). Next, in the 17
beta-estradiol assay, there was not a statistically significant difference between the stressed and
unstressed cells, and there was also no statistical significant difference across the four
concentrations of 17 beta-estradiol used (2-Way ANOVA, Stressed, Fi,32=3.001, P=0.093;
Concentration, F3,32=1.863, P=0.156; Figure 3). In the equilin assay, there was no statistical
significance between oxidative stress levels of the stressed and unstressed cells, and there was not a
statistical significance across the four concentrations of equilin used (2-way ANOVA, Stressed,
Fi,32=0.067, P=0.797; Concentration, F3,32=0.148, P=0.930; Figure 4). Finally, in the equilenin
assay, there was again no statistical significance between the stressed and unstressed cells, and
there was not a statistical significance among the four concentrations of equilenin used. (2-way
ANOVA, Stressed, Fi,32=1.147, P=0.292; Concentration, F3,32=1.417, P=0.256; Figure 5).
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DISCUSSION

In summary, the results showed no significant difference across the four different
estrogen concentrations utilized, between lOnM-lOpM. In addition, the results showed only the
17 alpha-estradiol assay had a statistically significant difference in oxidative stress levels across
the different estrogen concentrations when comparing astrocytes which received a 600 pM
hydrogen peroxide treatment and astrocytes which did not receive any hydrogen peroxide. This
may indicate that there may be an additive negative interaction when combining 17 alphaestradiol and hydrogen peroxide. Future studies should test to see if this is valid. Finally, there
was no significant difference between the oxidative stress levels of the positive control, in which
astrocytes were exposed to hydrogen peroxide, and the negative control, in which astrocytes
were not exposed to hydrogen peroxide.
The absence of a significant difference between the positive and negative controls could
be the result of a couple factors. First, it is possible the one hour hydrogen peroxide exposure
time was not long enough to significantly stress the astrocytes. It is also possible the 600 pM
concentration is not concentrated enough to induce stress to the astrocytes. However, this seems
unlikely as a previous study by Grimes and Hughes showed a one hour treatment with 600 pM
hydrogen peroxide to successfully stress astrocytes (2015). Therefore, it is more likely that
another factor is responsible for the inconsistency. Specifically, it is hypothesized that trypsin is
responsible for the discrepancy. Trypsin is a proteolytic enzyme used to lyse cadherin molecules
involved in cell adhesion (Descargues et al., 2006). Therefore, in this study, trypsin was used to
facilitate the dissociation of astrocytes both from other astrocytes as well as the culture substrate.
However, trypsin has been shown to lyse other cell surface proteins, which eventually leads to

the deterioration of cells (Huang et al., 2010). Thus, it is thought that trypsin, itself, is stressful to
cells and could induce oxidative stress in astrocytes. Unfortunately, the trypsin exposure time
was not as tightly controlled as was hoped, and different trials required different trypsin exposure
periods for dissociation and eventual removal of the astrocytes. In future studies, a different
removal method is recommended, if possible, or a very tight control of trypsin exposure.
Seeing as there was not a significant difference in oxidative stress levels between the
positive and negative controls, it is still largely unknown if short term estrogen exposures have
protective effects on astrocytes exposed to oxidative stressful conditions. However, even with the
external oxidative stress induction being unsuccessful, the results still suggest one meaningful
conclusion. Even in those relatively unstressed astrocytes, which were not exposed to any
purposeful induction of oxidative stress, there is always some natural oxidative stress present.
Therefore, the results indicate that modifying estrogen concentrations has no effect on the
oxidative stress levels in the unstressed astrocyte populations. Accordingly, it is possible that
estrogen does not have an effect on oxidative stress with a relatively shorter treatment time of
one or two hours.
Assuming that estrogen did not have an effect on oxidative stress levels in astrocytes, it is
possible that estrogen is neuroprotective to astrocytes for alternative reasons. One possible
alternative is that estrogen is neuroprotective by reducing apoptosis in astrocytes. One such study
has shown estradiol to have this capability by upregulating expression of the bcl-2 gene, a gene
known to decrease apoptosis, especially after ischemic injuries (Dubai et al., 1999). This is
further supported by Grimes and Hughes, in which they showed both 17 beta-estradiol and
equine estrogens to be effective in reducing hydrogen peroxide induced apoptosis. Although, in
that study, the astrocyte cell line originated from mouse cerebellum (C8-D1 A), instead of the
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human astrocyte cell line used in our study. Additionally, estrogen has also been shown to be
protective by increasing expression of certain cytokine molecules. For instance, estradiol has
been shown to upregulate the expression and secretion of transforming growth factor-P (TGF-P),
a cytokine molecule with known neuroprotective benefits (Dhandapani et al., 2005). Finally,
estrogens may be neuroprotective by upregulating expression of the glutamine synthetase gene in
astrocytes (Mong and Blutstein, 2006). This gene is critical in astrocytes as it increases
glutamine production, which is necessary for neuronal survival (Mong and Blutstein, 2006).
Therefore, there are a number of alternative mechanisms, besides reducing oxidative stress, in
which estrogens are thought to protect astrocytes.
Finally, it is of relevance to discuss estrogen’s possible signaling pathways. Estrogen, a
lipid steroid molecule, follows one of two possible signaling pathways after it diffuses into the
cell. First, there is a non-genomic signaling pathway, in which estrogen binds to the G proteincoupled receptor, GPR30, inducing a release of calcium ions from the endoplasmic reticulum
(Weatherman, 2006). By employing the one hour estrogen pretreatment, we sought to discover if
estrogen is neuroprotective via some rapid signaling pathway, such as this. However, it is also
possible that estrogen is neuroprotective via a genomic signaling pathway. For instance, in an
alternative signaling pathway estrogen has been shown to influence ligand activated transcription
by binding to the ERa and ERP receptors inside the cell (Weatherman, 2006). These
transcriptional effects require more time and thus would not show up with the one hour estrogen
pretreatment. Considering this, further inquiry into the effects of longer estrogen treatment times
should be explored, such as a 24-48 hour pretreatment with estrogen. Altogether, more research
is required to elucidate estrogen’s effects on astrocyte cells.
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Table 1. The treatment design depicting the 34 different populations of astrocytes cultured in a
96 well plate. Each estrogen was tested at four concentrations: lOnM, lOOnM, lpM, lOpM. One
half of the astrocytes were exposed to 600 pM H2O2. Finally, there were two control groups
without any estrogen. There was one negative control astrocyte population without H2O2
exposure, and another positive control astrocyte population that was exposed to H2O2.
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Hydrogen Peroxide Treatment
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Induced Oxidative Stress
Figure 4. The average (+/- 1 S.E.) percentage of ROS (-) astrocytes of the
negative control (left) and the positive control (right) when compared to the
unstressed negative control.
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Figure 2. The average (+/- 1 S.E.) percentage of ROS (-) astrocytes compared to
unstressed controls across four concentrations of 17 alpha-estradiol.
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Figure 3. The average (+/- 1 S.E.) percentage of ROS (-) astrocytes compared to
unstressed controls across four concentrations of 17 beta-estradiol.
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Figure 4. The average (+/- 1 S.E.) percentage of ROS (-) astrocytes compared to
unstressed controls across four concentrations of equilin.
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Figure 5. The average (+/- 1 S.E.) percentage of ROS (-) astrocytes compared to
unstressed controls across four concentrations of equilenin.
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